Nexalin Technology (NASDAQ:NXL) Posts Quarterly Earnings Results

Nexalin Technology (NASDAQ:NXLGet Free Report) released its quarterly earnings data on Friday. The company reported ($0.28) EPS for the quarter, Zacks reports. The business had revenue of $0.03 million during the quarter. Nexalin Technology had a negative net margin of 3,407.98% and a negative return on equity of 187.59%.

Nexalin Technology Stock Up 10.3 %

Shares of NASDAQ:NXL opened at $2.15 on Friday. The stock has a market cap of $28.60 million, a price-to-earnings ratio of -3.36 and a beta of 4.33. The firm’s 50 day moving average price is $2.85 and its 200 day moving average price is $2.47. Nexalin Technology has a fifty-two week low of $0.35 and a fifty-two week high of $4.49.

Analysts Set New Price Targets

Separately, Maxim Group reiterated a “hold” rating on shares of Nexalin Technology in a research report on Thursday, December 5th.

Read Our Latest Analysis on NXL

About Nexalin Technology

(Get Free Report)

Nexalin Technology, Inc, a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia.

Further Reading

Earnings History for Nexalin Technology (NASDAQ:NXL)

Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.